Trimel Pharmaceuticals (OTCMKTS:TRLPF) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Shares of Trimel Pharmaceuticals (OTCMKTS TRLPF) opened at $0.29 on Friday. Trimel Pharmaceuticals has a one year low of $0.08 and a one year high of $0.40. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.81 and a quick ratio of 0.94.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at

Trimel Pharmaceuticals Company Profile

Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trimel Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trimel Pharmaceuticals Corp. and related companies with's FREE daily email newsletter.